Research programme: GPBAR1 protein agonist - SatRx
Latest Information Update: 27 Sep 2016
At a glance
- Originator SatRx
- Class Small molecules
- Mechanism of Action GPBAR1 protein agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 27 Sep 2016 Preclinical trials in Type-2 diabetes mellitus in Russia (unspecified route) prior to September 2016 (SatRx pipeline, September 2016)